Lv4
470 积分 2022-01-25 加入
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
26天前
已完结
Unlocking the therapeutic potential of HDAC inhibitors in colorectal cancer: Mechanisms, efficacy, and future perspectives
26天前
已完结
HDAC and PI3K dual inhibitors in the treatment of cancers: Current status, trends, and solutions
26天前
已完结
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)
1个月前
已完结
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
1个月前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
2个月前
已完结
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
2个月前
已完结
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2个月前
已完结
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
2个月前
已完结
Abstract RF7-02: Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor (EPIK-B5): Phase III, randomized, double-blind, placebo-controlled, multicenter study
2个月前
已关闭
皖公网安备34019202002308
